Status:
ACTIVE_NOT_RECRUITING
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanc...
Eligibility Criteria
Inclusion
- Clinical stage III B/ III C with unsuitable for radical irradiation, Clinical stage IV or recurrent non-small cell lung cancer
- Life expectancy of at least 3 months
- Patients with ECOG performance status 0 or 1
Exclusion
- Patients with severe complication
- Patients with multiple primary cancers
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06542731
Start Date
June 1 2021
End Date
December 31 2026
Last Update
August 7 2024
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Saitama Cancer Center
Shinden, Saitama, Japan
2
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
3
Juntendo University Hospital
Bunkyō City, Japan
4
Teikyo University Hospital
Itabashi-ku, Japan